Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00765102 · ClinicalTrials.gov registry record · Phase 2
Trial of Romidepsin and Bortezomib for Multiple Myeloma
A Phase 2 study, sponsored by Celgene.
- Terminated
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
NCT00765102 is a Phase 2 study that was terminated before completion, run by Celgene. The registered enrollment target is 32 participants.
The verdict
NCT00765102, a Phase 2 study, was terminated before completion, sponsored by Celgene.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
Study Summary
This is a phase II, open-label, multicenter, dual-strata study designed to evaluate the efficacy and safety of IV romidepsin given in combination with IV bortezomib for multiple myeloma (MM) patients with refractory or relapsed disease. Patients will be enrolled into one of two strata, bortezomib-resistant or bortezomib non-resistant.
Interventions
- DRUG Bortezomib
- DRUG Romidepsin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2008-09-01 |
| Est. Completion | 2010-03-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00765102
The ClinicalTrials.gov registry entry for NCT00765102 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Bortezomib is the first listed.
NCT00765102 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00765102 about?
NCT00765102 is a clinical study titled "Trial of Romidepsin and Bortezomib for Multiple Myeloma". This is a phase II, open-label, multicenter, dual-strata study designed to evaluate the efficacy and safety of IV romidepsin given in combination with IV bortezomib for multiple myeloma (MM) patients with refractory or relapsed disease. Patients will be enrolled into one of two strata, bortezomib-re...
What is the current status of trial NCT00765102?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2008-09-01. Estimated completion is 2010-03-01.
What interventions are being tested in trial NCT00765102?
The interventions under investigation include: Bortezomib (DRUG), Romidepsin (DRUG).
Who is sponsoring clinical trial NCT00765102?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.